BMS’ Breyanzi gets FDA accelerated approval for follicular lymphoma
The approval is based on results from open-label, global, multicentre, Phase 2, single-arm TRANSCEND FL study in which 95.7% of patients responded to the CAR T cell therapy
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
The approval is based on results from open-label, global, multicentre, Phase 2, single-arm TRANSCEND FL study in which 95.7% of patients responded to the CAR T cell therapy
DoH and GSK will work together to maximise the strategic and healthcare
China’s NMPA approved Nefecon in late 2023 for the treatment of primary
GenoBlend is made from premium ingredients, including organic pea protein, organic brown
Upstaza is a one-time gene replacement therapy intended for patients aged 18